| Schedule of consolidated net loss summarized by the significant segment expenses regularly reviewed by the CODM |
The following table presents consolidated net loss summarized by the significant segment expenses regularly reviewed by the CODM for the years ended June 30, 2026, and 2025 (in thousands): | | | | | | | | | 2026 | | 2025 | Research and development: | | | | | | | Ersodetug | | $ | 24,150 | | $ | 31,752 | Compensation and benefits | | | 23,434 | | | 19,404 | Other research and development segment expenses (1) | | | 6,214 | | | 10,371 | Total research and development | | | 53,798 | | | 61,527 | General and administrative: | | | | | | | Compensation and benefits | | | 16,954 | | | 10,756 | Other general and administrative segment expenses (2) | | | 12,214 | | | 7,611 | Total general and administrative | | | 29,168 | | | 18,367 | Operating loss | | | (82,966) | | | (79,894) | Total non-operating income, net | | | 5,380 | | | 5,482 | Net loss | | $ | (77,586) | | $ | (74,412) |
| (1) | Other R&D segment expenses primarily include licensing costs, quality regulatory and other pipeline development costs, employee travel and expense, and other facility and information technology costs. |
| (2) | Other G&A segment expenses primarily include consulting expenses related to business development and market planning activities, insurance expense, public company costs, employee travel and expense, and other facility and information technology costs. |
|